# Anticoagulants & Antiplatelets
<!-- toc -->
## Hemostasis Big Picture
### High Pressure Circuits
* Disorders: Ischemic Stroke, Early phase of Myocardial Infarction, Peripheral Vascular Disease
* **Main clotting player: Platelets**
* Use Antiplatelets (i.e. Aspirin)
### Low Pressure Circuits
* Disorders: DVT, PE, Atrial Fibrillation, Dural Sinus Thrombosis, Late phase Myocardial Infarction
* **Main clotting player: Coagulation factors leading to fibrin clot**
* Use Anticoagulants (i.e. Heparin, Warfarin)

## Anticoagulants Big Picture
### How to prevent formation of fibrin clot?
* Inhibit **Factor 10,9,7,2,C, S**
  * Warfarin
* **Activate Antithrombin decreasing the action of Thrombin (Factor 2) and Factor 10**
  *  Heparin
* Inhibit **Factor Xa**
  *  Oral: Apixaban, Rivaroxaban
  * |V/SC: Enoxaparin, Fondaparinux
* Inhibit **Thrombin (Factor 2)**
  * Bivalirudin IV, Argatroban IV, Dabigatran PO
### How to **break down fibrin clot?**
* **Activate plasmin which breaks down fibrin clot**: Alteplase, Streptokinase

## Anticoagulants
### Warfarin

**MOA**: Inhibits carboxylation of vitamin K dependent factors, 10, 9, 7, 2, Protein C, Protein S
* Effect on extrinsic pathway
* Prolongs **PT/INR**

**Use**
* DVT/PE
* A Fib

**Notes**
* Pharmacogenomics differences in metabolism
* Metabolized via CYP enzymes- Prolonged half life ~ 5 days
* **Multiple drug-drug interactions**
* Advise patients on stable amount of greens containing vitamin K

**Side Effects**
* Bleeding
* Teratogenic
* **Warfarin induced tissue necrosis**
* Warfarin inhibits Protein C,S in addition to 10, 9, 7,2
* Protein C,S which have anticoagulant properties have half life than 10,9,7,2
* Hypercoagulability state resulting in microthrombi and skin necrosis
* Tx: Bridge with heparin in the initial phase to inhibit factors 10,2

**Warfarin Reversal**
* Prothrombin Concentrate (2,9.10)-Quick
* FFP (VitK factors + Factor V)-Quick
* Vitamin K-Takes time

### Heparin

**MOA**: Activates Antithrombin which lowers the activity of thrombin (2) and factor 10
* Affects the intrinsic pathway
* Monitor using PTT

*Heparin has a short half life*

**Use**
* Acute DVT/PE
* Acute Coronary Syndrome (Ml)

**Side Effects**
* Bleeding
* ***Heparin induced thrombocytopenia***
  * IgG antibodies against heparin bound platelet factor (PF4)
  * Antibody complexes with platelets
  * Thrombosis and thrombocytopenia

**Reversal**
* Protamine
  * Binds to Heparin

### Factor Xa Inhibitors
*Parenteral*: **Enoxaparin, Fondaparinux**

**MOA**: Inhibit Factor Xa

*Longer half life than unfractionated heparin*

**Use**
* Same as heparin
* DVT/PE
* AFib

**SE**
* Less incidence of HIT
* Fondaparinux sometimes used in patients with HIT allergy
* No Reversal

*Oral*: **Apixaban, Rivaroxaban**

**MOA**: Inhibit Factor Xa

*No need for monitoring*

**Use**
* Chronic DVT/PE
* A.Fib

**SE**
* **Bleeding not easily reversible**

### Thrombin Inhibitors
**Bivalirudin IV, Argatroban IV, Dabigatran PO**

**MOA**: Directly inhibit activity of free and clotted thrombin

**Use**
* **Dabigatran**: DVT, A. fib
* **Argatroban**: HIT allergic patients
* **Bivalirudin**: Patients undergoing percutaneous coronary stenting- prevent stent thrombosis

**SE**
* Bleeding
  * Reverse Dabigatran with idarucizumab

### Fibrinolytics and their inhibitors

#### Fibrinolytics
**Altepase, Streptokinase**

**MOA**:
* Altepase is naturally occurring enzyme
* Converts plasminogen to plasmin which cleaves thrombin and fibrin clots

**Indications**
* MIif no PCI Available
* Early Ischemic stroke
* Large Saddle PE

**Side Effects**
* Severe bleeding
  * Reversal with antifibrinolytics

#### Inhibitors
**Aminocaproic Acid, Tranexamic Acid**
**MOA**: Inhibits plasminogen activation

**Use:**
* Bleeding from fibrinolytics
* Bleeding from surgery

**Side Effects**
* Thrombosis

### Antiplatelets Big Picture
#### Platelet receptors
* **Gplib/llla**
  * Binds platelets together using **fibrinogen**
* **Gp1b**
  * Binds endothelial surfaces using **vW factor**
#### How to inhibit *platelet aggregation*?
* Inhibit **TXA2 synthesis**: Aspirin
* **Decrease cAMP expression**: Cilostazol, Dipyridamole,
* **Inhibit exposure of Gpllb/llla on surface of receptors**: Clopidogrel, Prasugrel, Ticlopidine
* **Directly inhibit Gplib/llla receptors**: Abciximab, Eptifibatide

## Antiplatelets
### Aspirin

**MOA**
* **Irreversibly** inhibit COX 1 inhibiting synthesis of TXA2 inhibiting platelet aggregation
* Inhibition lasts the half life of platelets ~5-7 days

**Use**
* Primary prevention of MI
* Acute M|
* Ischemic stroke/TIA prevention and treatment

**Side Effects**
* Discussed previously
* Bleeding

### ADP Inhibitors
**Clopidogrel, Prasugrel, Ticagrelor**

**MOA**
* Irreversibly block P2Y12 subtype of ADP receptor
* ADP responsible for expression of Gpllb/llla
* Gbllb/llla binds fibrin and causes platelet aggregation and thrombus

**Use**
* Myocardial infarction, decrease thrombosis of coronary stents, Recurrent ischemic thrombotic stroke

**Side Effects**
* Bleeding

### Direct GplIb/IllA Inhibitors
**Abciximab, Eptifibatide**

**MOA**: Direct inhibitors of Gpllb/llla on activated platelets preventing aggregation

**Use**
* Percutaneous coronary angioplasty

**Side Effects**
* Thrombocytopenia

### cAMP Inhibitors
**Cilostazol, Dipyridamole**

**MOA**: Phosphodiesterase inhibitors- Inhibiting breakdown of cAMP leading to decrease in platelet aggregation

**Use**
* **Peripheral vascular disease- Cilostazol**
* Prevention of stroke/TIA- Dipyridamole + Aspirin

**Side Effects**
* Bleeding
* Facial flushing
* Hypotension

## Myocardial Infarction Treatment
### Acute Phase of Ml
* Initial Treatment (MONA)
  * **Morphine**: Pain & Vasodilator
  * **02**: Vasodilator
  * **Nitroglycerin**: Decreases myocardial demand
  * **Aspirin**: Decreases further thrombus propagation
  * **+/- Heparin/Enoxaparin**: Prevent further thrombus propagation
*  Reperfusion
  * 1st line: **Coronary Balloon Angiography and stent** (Cath Lab)
  * 2nd line: **Alteplase** (Fibrinolytic) if no cath lab available
### Subacute Phase of MI- Medical Management
* **Antiplatelet**: Aspirin & Clopidogrel (to prevent stent occlusion)
* **Beta Blocker & ACE Inhibitor**: ****Proven mortality benefit****
* **High Intensity Statin**: Decrease atherosclerosis

## Stroke Treatment
### Ischemic Stroke
* Acute phase
  * Thrombolysis using **Altepase** (tPA) if meets certain criteria
* Subacute phase
  * **Antiplatelets**
    * **Aspirin** for first Stroke and/or TIA
    * **Clopidogrel** for recurrent strokes
  * **High intensity statin**
  * **Anticoagulant** if cardioembolic source (i.e. atrial fibrillation)
    * Warfarin or Xa inhibitors
  * **BP Control**
### Hemorrhagic Stroke (Intraparenchymal bleed or Subarachnoid hemorrhage)
* **BP Control** to prevent more bleeding
* **Nimodipine** for SAH: Prevent cerebral vasospasm

## DVT/PE Treatment
#### Acute DVT/PE
* Heparin/Enoxaparin/Fondaparinux: Prevent further thrombus propagation
#### Acute Saddle PE affecting Hemodynamics
* Altepase
#### Chronic DVT/PE
* Warfarin
* Oral Anti-Xa Inhibitors
* Dabigatran
* Enoxaparin, Heparin in pregnant patients
#### DVT Prophylaxis for high risk patients
* Enoxaparin/Heparin
* Oral Anti-Xa inhibitors
